Sweden
· Delayed Price · Currency is SEK Hansa Biopharma AB Company Description
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe.
The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test.
It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis.
In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation.
It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies.
Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
| Country | Sweden |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 135 |
| CEO | Søren Tulstrup |
Contact Details
Address: ScheelevAegen 22 Lund, 223 63 Sweden | |
| Phone | 46 46 16 56 70 |
| Website | hansabiopharma.com |
Stock Details
| Ticker Symbol | HNSA |
| Exchange | Nasdaq Stockholm |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0002148817 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Søren Tulstrup M.Sc | President and Chief Executive Officer |
| C. Evan Ballantyne | Chief Financial Officer and Senior Vice President |
| Eva-Maria Joed | Vice President of Finance and Administration |
| Klaus Sindahl | Vice President and Head of Investor Relations |
| Anne Säfström Lanner | Senior Vice President and Chief Human Resources Officer |
| Emanuel Björne | Vice President and Head of Business Development |
| Dr. Lena Winstedt | Head of Science |
| Vincenza Nigro M.B.A. | Vice President and Head of Medical Affairs |
| Dr. Magnus Korsgren | Vice President and Head of Research and Development |
| Dr. Hitto Kaufmann Ph.D. | Senior Vice President, Chief Research & Development Officer |